Sanofi Names Belen Garijo to Replace Paul Hudson as CEO
By Billy Gray
Sanofi said Belen Garijo would succeed Paul Hudson as chief executive officer after the company's board of directors decided not to renew Hudson's mandate.
The French drugmaker said the decision to replace Hudson as CEO came in a board meeting on Feb. 11. Garijo will step into the top role at the end of the group's annual general meeting on April 29, while Hudson is set to step down on Feb. 17 at the close of business.
Sanofi thanked Hudson for his contributions to the company over the past six years.
Garijo has since 2021 been the CEO of Merck KGaA, which she joined in 2011. She previously worked for 15 years at Sanofi, where she was vice president of pharmaceutical operations for Europe and Canada and a member of the executive committee.
Olivier Charmeil, Sanofi's executive vice president, general medicines, will serve as interim CEO during the leadership transition, the company said.
Write to Billy Gray at william.gray@wsj.com
(END) Dow Jones Newswires
February 12, 2026 02:10 ET (07:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for November
This Once-Hot AI Stock Now Looks Deeply Undervalued
The 10 Best Companies to Invest in Now
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
United States